See more : Polymetal International plc (POYYF) Income Statement Analysis – Financial Results
Complete financial analysis of Agree Realty Corporation (ADC) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Agree Realty Corporation, a leading company in the REIT – Retail industry within the Real Estate sector.
You may be interested
- Del Taco Restaurants, Inc. (TACO) Income Statement Analysis – Financial Results
- Orford Mining Corporation (ORMFF) Income Statement Analysis – Financial Results
- Eversource Energy (ES) Income Statement Analysis – Financial Results
- Ashoka Metcast Limited (ASHOKAMET.NS) Income Statement Analysis – Financial Results
- Tokuyama Corporation (TKYMY) Income Statement Analysis – Financial Results
Agree Realty Corporation (ADC)
About Agree Realty Corporation
Agree Realty Corporation is a publicly traded real estate investment trust primarily engaged in the acquisition and development of properties net leased to industry-leading retail tenants. As of September 30, 2020, the Company owned and operated a portfolio of 1,027 properties, located in 45 states and containing approximately 21.0 million square feet of gross leasable area. The Company's common stock is listed on the New York Stock Exchange under the symbol ADC.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 537.50M | 463.15M | 363.61M | 248.57M | 187.48M | 148.20M | 116.56M | 91.53M | 69.97M | 53.56M | 43.52M | 35.79M | 36.32M | 36.11M | 37.26M | 35.65M | 34.47M | 32.91M | 31.58M | 29.93M | 27.47M | 25.82M | 24.68M | 23.73M | 21.93M | 19.67M | 18.23M | 16.29M | 13.80M | 9.50M |
| Cost of Revenue | 239.67M | 85.62M | 65.34M | 31.75M | 23.51M | 17.01M | 12.47M | 8.60M | 6.38M | 4.92M | 3.66M | 3.58M | 4.91M | 3.85M | 2.43M | 64.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 297.83M | 377.53M | 298.26M | 216.82M | 163.97M | 131.18M | 104.09M | 82.93M | 63.59M | 48.64M | 39.86M | 32.21M | 31.41M | 32.26M | 34.83M | 35.59M | 34.47M | 32.91M | 31.58M | 29.93M | 27.47M | 25.82M | 24.68M | 23.73M | 21.93M | 19.67M | 18.23M | 16.29M | 13.80M | 9.50M |
| Gross Profit Ratio | 55.41% | 81.51% | 82.03% | 87.23% | 87.46% | 88.52% | 89.30% | 90.61% | 90.88% | 90.82% | 91.60% | 90.00% | 86.48% | 89.34% | 93.49% | 99.82% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 0.00 | 0.37 | 0.37 | 0.37 | 0.43 | 0.43 | 0.50 | 0.50 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 34.79M | 30.12M | 25.46M | 20.79M | 15.57M | 12.17M | 9.95M | 8.02M | 6.99M | 6.63M | 5.95M | 5.68M | 5.66M | 5.00M | 4.56M | 6.94M | 4.46M | 4.02M | 4.19M | 2.85M | 2.28M | 2.01M | 1.81M | 1.56M | 1.42M | 1.17M | 1.11M | 1.10M | 1.00M | 700.00K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 88.00 | -384.00 | 859.00K | -2.58M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 34.79M | 30.12M | 25.46M | 20.79M | 15.57M | 12.17M | 9.95M | 8.02M | 6.99M | 6.63M | 5.95M | 5.68M | 5.66M | 5.00M | 5.42M | 4.36M | 4.46M | 4.02M | 4.19M | 2.85M | 2.28M | 2.01M | 1.81M | 1.56M | 1.42M | 1.17M | 1.11M | 1.10M | 1.00M | 700.00K |
| Other Expenses | 0.00 | 133.57M | 95.73M | 66.76M | 45.70M | 4.00K | 347.00K | 23.41M | 16.49M | 11.10M | 8.49M | 6.47M | 6.50M | 5.69M | 7.65M | 7.25M | 9.33M | 9.07M | 9.19M | 8.96M | 7.58M | 8.19M | 7.99M | 7.46M | 6.95M | 6.12M | 5.57M | 5.11M | -5.60M | -4.20M |
| Operating Expenses | 216.39M | 163.69M | 121.19M | 87.55M | 61.27M | 55.86M | 41.70M | 31.42M | 23.47M | 17.73M | 14.44M | 12.15M | 12.16M | 10.69M | 14.63M | 19.37M | 13.79M | 13.09M | 13.38M | 11.81M | 9.86M | 10.20M | 9.79M | 9.02M | 8.37M | 7.29M | 6.67M | 6.21M | -4.60M | -3.50M |
| Cost & Expenses | 283.11M | 249.31M | 186.53M | 119.30M | 84.78M | 72.87M | 54.17M | 40.02M | 29.85M | 22.65M | 18.10M | 15.73M | 17.07M | 14.54M | 14.63M | 19.37M | 13.79M | 13.09M | 13.38M | 11.81M | 9.86M | 10.20M | 9.79M | 9.02M | 8.37M | 7.29M | 6.67M | 6.21M | -4.60M | -3.50M |
| Interest Income | 0.00 | 63.44M | 50.38M | 40.10M | 33.09M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 770.18K | 1.25M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 81.12M | 63.44M | 66.35M | 44.66M | 32.98M | 0.00 | 0.00 | 0.00 | 0.00 | 8.59M | 6.48M | 5.13M | 4.73M | 4.71M | 4.64M | 5.18M | 4.90M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 209.37M | 212.74M | 162.25M | 123.44M | 86.39M | 64.12M | 54.17M | 40.02M | 16.49M | 11.10M | 8.49M | 6.47M | 6.50M | 5.69M | 5.71M | 5.39M | 5.20M | 4.99M | 207.04K | 4.62M | 4.82M | 4.22M | 4.22M | 4.06M | 3.80M | 3.51M | 3.19M | 3.03M | 2.60M | 2.00M |
| EBITDA | 463.95M | 386.24M | 295.67M | 192.16M | 161.45M | 118.63M | 94.14M | 74.92M | 56.60M | 42.01M | 34.05M | 26.19M | 19.73M | 14.85M | 28.34M | 21.67M | 25.88M | 24.81M | 23.15M | 17.57M | 19.81M | 19.17M | 17.97M | 18.24M | 17.29M | 15.89M | 14.75M | 13.11M | 21.00M | 15.00M |
| EBITDA Ratio | 86.32% | 74.08% | 75.47% | 77.31% | 72.92% | 74.33% | 68.59% | 71.33% | 63.81% | 78.44% | 77.92% | 74.12% | 74.44% | 96.81% | 76.05% | 60.77% | 72.05% | 75.39% | 72.28% | 75.26% | 87.07% | 74.23% | 72.83% | 76.87% | 78.84% | 80.75% | 80.91% | 76.46% | 152.17% | 157.89% |
| Operating Income | 254.39M | 218.09M | 190.27M | 125.13M | 101.09M | 73.00M | 62.39M | 51.51M | 40.11M | 27.89M | 25.42M | 20.06M | 15.60M | 13.87M | 22.63M | 16.28M | 20.68M | 19.82M | 18.21M | 18.12M | 16.65M | 15.62M | 15.10M | 14.71M | 13.56M | 12.38M | 11.56M | 10.08M | 18.40M | 13.00M |
| Operating Income Ratio | 47.33% | 47.09% | 52.33% | 50.34% | 53.92% | 49.26% | 53.53% | 56.28% | 57.33% | 52.07% | 58.41% | 56.05% | 42.94% | 38.42% | 60.73% | 45.67% | 59.99% | 60.23% | 57.65% | 60.54% | 60.61% | 60.50% | 61.20% | 61.98% | 61.83% | 62.93% | 63.40% | 61.88% | 133.33% | 136.84% |
| Total Other Income/Expenses | -80.93M | -62.19M | -64.99M | -40.07M | -33.09M | -13.69M | -3.37M | -5.71M | -351.00K | -9.12M | -6.47M | -5.13M | 506.14K | -4.71M | 0.00 | -14.46M | 1.04M | -4.62M | 12.79K | -4.29M | 176.08K | 673.58K | 1.13M | 522.34K | 68.61K | 0.00 | 0.00 | 653.07K | 0.00 | 0.00 |
| Income Before Tax | 173.46M | 155.90M | 125.28M | 93.06M | 81.30M | 59.31M | 58.79M | 45.80M | 39.76M | 18.78M | 18.95M | 14.92M | 9.55M | 15.07M | 15.48M | 15.48M | 21.72M | 0.00 | 18.22M | 18.34M | 15.17M | 16.30M | 16.23M | 15.23M | 13.63M | 0.00 | 0.00 | 10.73M | 0.00 | 0.00 |
| Income Before Tax Ratio | 32.27% | 33.66% | 34.45% | 37.44% | 43.37% | 40.02% | 50.44% | 50.04% | 56.83% | 35.05% | 43.54% | 41.70% | 26.30% | 41.72% | 41.55% | 43.42% | 63.02% | 0.00% | 57.69% | 61.27% | 55.21% | 63.11% | 65.78% | 64.18% | 62.14% | 0.00% | 0.00% | 65.89% | 0.00% | 0.00% |
| Income Tax Expense | 2.91M | 2.86M | 2.40M | 1.09M | 538.00K | 516.00K | 4.62M | 6.39M | 1.10M | 8.87M | -728.73K | -3.13M | 9.70M | 6.51M | -9.83M | -13.20M | 5.20M | 5.84M | 6.58M | 5.00M | 7.14M | 6.85M | 6.82M | 7.61M | 6.75M | 6.29M | 6.34M | 6.35M | 15.20M | 12.70M |
| Net Income | 169.96M | 152.44M | 122.27M | 91.38M | 80.08M | 58.17M | 58.11M | 45.12M | 39.02M | 18.49M | 19.68M | 18.05M | 9.55M | 15.07M | 17.99M | 15.02M | 15.48M | 13.97M | 16.05M | 13.12M | 10.47M | 8.77M | 8.07M | 7.10M | 6.81M | 6.09M | 5.22M | 3.73M | 3.20M | 300.00K |
| Net Income Ratio | 31.62% | 32.91% | 33.63% | 36.76% | 42.71% | 39.25% | 49.86% | 49.29% | 55.77% | 34.52% | 45.21% | 50.43% | 26.30% | 41.72% | 48.29% | 42.12% | 44.92% | 42.46% | 50.82% | 43.85% | 38.12% | 33.97% | 32.68% | 29.91% | 31.04% | 30.94% | 28.63% | 22.92% | 23.19% | 3.16% |
| EPS | 1.70 | 1.84 | 1.79 | 1.76 | 1.96 | 1.81 | 2.09 | 1.97 | 2.17 | 1.24 | 1.51 | 1.63 | 0.99 | 1.54 | 2.20 | 1.91 | 2.02 | 1.84 | 2.15 | 2.03 | 1.63 | 1.99 | 1.81 | 1.61 | 1.56 | 1.40 | 1.41 | 1.41 | 1.23 | 0.08 |
| EPS Diluted | 1.70 | 1.83 | 1.78 | 1.74 | 1.93 | 1.80 | 2.08 | 1.97 | 2.16 | 1.24 | 1.50 | 1.62 | 0.99 | 1.54 | 2.14 | 1.91 | 2.01 | 1.83 | 2.14 | 2.03 | 1.63 | 1.97 | 1.81 | 1.61 | 1.56 | 1.40 | 1.41 | 1.41 | 1.23 | 0.08 |
| Weighted Avg Shares Out | 95.19M | 78.66M | 66.80M | 51.84M | 40.58M | 32.07M | 27.63M | 22.87M | 18.00M | 14.88M | 13.07M | 11.07M | 9.64M | 9.76M | 7.90M | 7.68M | 7.65M | 7.59M | 7.46M | 6.46M | 4.88M | 4.45M | 4.42M | 4.41M | 4.36M | 4.36M | 3.69M | 2.65M | 2.60M | 3.21M |
| Weighted Avg Shares Out (Dil) | 95.44M | 79.16M | 67.14M | 52.40M | 41.22M | 32.40M | 27.70M | 22.96M | 18.07M | 14.97M | 13.16M | 11.14M | 9.68M | 9.76M | 8.42M | 8.38M | 7.72M | 7.64M | 7.50M | 6.46M | 5.26M | 4.45M | 4.42M | 4.41M | 4.36M | 4.36M | 3.69M | 2.65M | 2.60M | 3.21M |
Agree Realty: Quality Always Rises To The Top
Agree Realty remains a top-quality REIT with strong fundamentals, despite a less attractive yield compared to a year ago, offering solid long-term upside potential. The company has demonstrated robust growth in AFFO and core FFO, with effective capital allocation and...
Agree Realty Announces Exercise of Underwriters' Option and Closing of Forward Offering of Common Stock
ROYAL OAK, Mich. , Oct. 28, 2024 /PRNewswire/ -- Agree Realty Corporation (NYSE: ADC) (the "Company") today announced that it has completed its public offering of 5,060,000 shares of its common stock, which includes the underwriters' full exercise of their option...
If I Could Own Only 4 Stocks In Retirement, It Would Be These
For retirees, I advise to own high-quality assets that balance growth, income, and stability. My preferred asset allocation includes 70% in equities and dividend-focused ETFs, 20% in short-duration fixed-income assets, and 10% in liquid savings. For equities, I prioritize blue-chip...
Brace For Volatility
U.S. equity markets snapped a six-week winning streak, while benchmark interest rates surged to three-month highs as investors braced for a volatile two-week stretch of market-moving events. Another surprisingly solid slate of domestic economic data - highlighted by improved jobless...
Agree Realty Announces Pricing of Upsized Forward Common Stock Offering
ROYAL OAK, Mich. , Oct. 24, 2024 /PRNewswire/ -- Agree Realty Corporation (NYSE: ADC) (the "Company") today announced the pricing of its public offering of 4,400,000 shares of its common stock at a public offering price of $74.00 per share...
Agree Realty Announces Common Stock Offering
ROYAL OAK, Mich. , Oct. 24, 2024 /PRNewswire/ -- Agree Realty Corporation (NYSE: ADC) (the "Company") today announced that it commenced an underwritten public offering of 4,000,000 shares of its common stock in connection with the forward sale agreements described below.
Agree Realty Q3 Earnings: Buying What They Are Selling
Agree Realty is a net lease REIT investing in single tenant retail properties and ground leases around the country. ADC reported Q3 earnings which were aligned with expectations. We talk cost of equity and explain what ADC's low yield means...
What I Wish I Knew Before Becoming A REIT Investor
REIT investing is more complicated than it may seem. There are many potential pitfalls that could ruin your returns. I share my 5 biggest lessons as a decade-long REIT investor.
This 4%-Yielding Dividend Stock Is Stepping on the Accelerator
Agree Realty offers an attractive and steadily rising stream of dividend income.
ZL-1310, an Investigational DLL3-Targeted Antibody-Drug Conjugate (ADC), Demonstrates Promising Objective Response Rates and Safety Profile in Extensive-Stage Small Cell Lung Cancer
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today presented data from the ongoing global Phase 1a/1b study of ZL-1310, a potential best-in-class next-generation antibody-drug conjugate (ADC), at the EORTC-NCI-AACR (ENA) Symposium 2024 in Barcelona, Spain, as...
Source: https://incomestatements.info
Category: Stock Reports